Australia's Orthocell gains most in over a year on US approval for nerve repair device

Orthocell

15/04/2026 03:51

** Shares of Australia's Orthocell OCC.AX rise as much as 23.6% to A$1.075, their biggest intraday pct gain since Dec 2, 2024

** Stock touches highest level since January 12

** Regenerative medicine co receives approval from the U.S. Department of Defence (DoD)

** Says approval for nerve repair device, Remplir to be used across DoD, Veterans Affairs hospital networks

** Stock down 3.2% YTD

 (Reporting by Aamir Sheik Khalid in Bengaluru)

 ((Aamir.SheikKhalid@thomsonreuters.com))